Enlivex Therapeutics Management
Management criteria checks 1/4
Enlivex Therapeutics' CEO is Oren Hershkovitz, appointed in Nov 2019, has a tenure of 5.25 years. directly owns 0.12% of the company’s shares, worth $27.53K. The average tenure of the management team and the board of directors is 5.3 years and 2.3 years respectively.
Key information
Oren Hershkovitz
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.3yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Sep 13
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Jul 25Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Apr 05Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Nov 16Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Sep 30Enlivex to gets US patent covering use of cell therapy Allocetra
Sep 06Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Aug 29Envilex Therapeutics reports Q2 results
Aug 22We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Jul 08Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Jul 06We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Mar 23Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Nov 25We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Aug 12Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy
Jun 15Enlivex issued new Canadian patent for Allocetra immunotherapy
Jun 01We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Apr 29Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 03Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Jan 11
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
Nov 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$19m |
| Jun 30 2024 | n/a | n/a | -US$22m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | n/a | n/a | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | n/a | n/a | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | n/a | n/a | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | n/a | n/a | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$296k | US$38k | -US$10m |
Compensation vs Market: Insufficient data to establish whether Oren's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Oren's compensation with company performance.
CEO
Oren Hershkovitz (47 yo)
5.3yrs
Tenure
US$295,600
Compensation
Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.1yrs | US$536.00k | 3.52% $ 836.0k | |
| Chief Executive Officer | 5.3yrs | US$295.60k | 0.12% $ 27.5k | |
| Founder and Scientific Advisor | no data | US$545.00k | 1.1% $ 261.7k | |
| Chief Financial Officer | 9.1yrs | US$132.00k | 0.0085% $ 2.0k | |
| Senior Director of Operations | 3.1yrs | no data | no data | |
| Director of HR | 3.1yrs | no data | no data |
5.3yrs
Average Tenure
52.5yo
Average Age
Experienced Management: ENLV's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.1yrs | US$536.00k | 3.52% $ 836.0k | |
| Independent Director | 1.8yrs | no data | no data | |
| Independent Director | 11.1yrs | no data | 0.82% $ 195.7k | |
| Clinical Advisor | no data | no data | no data | |
| Independent Vice Chairman of the Board | 2.8yrs | no data | 0% $ 0 | |
| Director | 4.2yrs | no data | 0.012% $ 3.0k | |
| Clinical Advisor | no data | no data | no data | |
| Clinical Advisor | 1.1yrs | no data | no data | |
| Clinical Advisor | 1.1yrs | no data | no data | |
| Independent Director | 11.1yrs | no data | 0.023% $ 5.5k | |
| Clinical Advisor | 1.1yrs | no data | no data | |
| Clinical Advisor | 1.1yrs | no data | no data |
2.3yrs
Average Tenure
59.5yo
Average Age
Experienced Board: ENLV's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/05 12:14 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enlivex Therapeutics Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |